ACE and prediabetes syndrome: Either angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) were used at a higher rate in patients with prediabetes while dihydropyridine calcium channel blocker (DHP-CCB) was used at a higher rate in participants with normoglycemia; however, the difference did not reach statistical significance (Table 2).